SCHEMBL19798975

SCHEMBL19798975

CON(C)C(=O)C1CC(C(F)(F)F)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.40
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
HPGD P15428 1/20 0.36
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
RORC P51449 1/20 0.34
TACR1 P25103 1/20 0.34
JAK1 P23458 2/20 0.34
USP30 Q70CQ3 2/20 0.33
PDE4B Q07343 1/20 0.33
RECQL P46063 1/20 0.33
EPHX1 P07099 1/20 0.33
USP2 O75604 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
JAK2 O60674 1/20 0.32
KDM4E B2RXH2 1/20 0.32
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL278133 0.85 NR1H2 (0.45) NR1H2DDB1CRBNHPGDMEN1
SCHEMBL17913758 0.84 RIPK1 (0.30)
SCHEMBL18485336 0.83 NR1H2 (0.43) NR1H2DDB1CRBNHPGDMEN1
SCHEMBL17913807 0.83 NR1H2 (0.43) NR1H2DDB1CRBNHPGDMEN1
SCHEMBL20281680 0.82 NR1H2 (0.43) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL21995658 0.81 NR1H2 (0.46) NR1H2HPGDMEN1ALDH1A1MAPT
SCHEMBL23230817 0.80 NR1H2 (0.55) NR1H2DDB1CRBNHPGDMEN1
SCHEMBL2992998 0.80 NR1H2 (0.55) NR1H2DDB1CRBNHPGDMEN1
SCHEMBL29745515 0.80 NR1H2 (0.55) NR1H2DDB1CRBNHPGDMEN1
SCHEMBL31453954 0.80 NR1H2 (0.46) NR1H2DDB1CRBNHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107406414-B (piperidin-3-yl) (naphthalen-2-yl) methanone derivatives as inhibitors of histone demethylase KDM2B for the treatment of cancer 基因泰克公司 2022-04-19 CN disclosed
US-10280149-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-05-07 US disclosed
US-20180022727-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-01-25 US disclosed
US-20180022727-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280149-B2 Therapeutic compounds and uses thereof KDM1B, KDM6B, KDM2B NR1H2 233/4885DDB1 762/4885CRBN 159/4885
US-20180022727-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF KDM1B, KDM6B, KDM2B NR1H2 233/4885DDB1 762/4885CRBN 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.